Bacterial vaginosis (BV) can sometimes be challenging to treat effectively. While standard oral antibiotics, such as metronidazole, are generally effective, some cases require switching to clindamycin for better outcomes. A recent open-label randomized controlled trial published in the New England Journal of Medicine in March 2025 evaluated the treatment of male partners with oral metronidazole and topical clindamycin cream. The primary outcome was the recurrence of BV in female partners within 12 weeks. The study found that treating male partners resulted in a significantly lower recurrence rate of BV compared to standard care in women alone.